FibroGen Inc (NASDAQ: FGEN) is -26.29% lower on its value in year-to-date trading and has touched a low of $0.18 and a high of $2.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FGEN stock was last observed hovering at around $0.39 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $0.39, the stock is -22.03% and -25.16% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.27 million and changing -0.94% at the moment leaves the stock -34.05% off its SMA200. FGEN registered -80.29% loss for a year compared to 6-month gain of 17.56%.
The stock witnessed a -15.74% loss in the last 1 month and extending the period to 3 months gives it a -7.29%, and is -3.22% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.22% over the week and 13.88% over the month.
FibroGen Inc (FGEN) has around 486 employees, a market worth around $39.33M and $180.01M in sales. Profit margin for the company is -67.66%. Distance from 52-week low is 116.83% and -86.06% from its 52-week high.
with sales reaching $24.91M over the same period.The EPS is expected to grow by 72.60% this year, but quarterly earnings will post 20.37% year-over-year. Quarterly sales are estimated to shrink -8.21% in year-over-year returns.
The shares outstanding are 100.77M, and float is at 94.10M with Short Float at 3.13%.
The top institutional shareholder in the company is PRIMECAP MANAGEMENT CO/CA/ with over 13.66 million shares valued at $12.19 million. The investor’s holdings represent 13.6785 of the FGEN Shares outstanding. As of 2024-06-30, the second largest holder is ARMISTICE CAPITAL, LLC with 8.94 million shares valued at $7.97 million to account for 8.9508 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 5.89 million shares representing 5.9458 and valued at over $5.25 million, while ACADIAN ASSET MANAGEMENT LLC holds 3.3703 of the shares totaling 3.36 million with a market value of $3.0 million.
FibroGen Inc (FGEN) Insider Activity
The most recent transaction is an insider purchase by Adib Deyaa, the company’s Chief Medical Officer. SEC filings show that Adib Deyaa bought 22,123 shares of the company’s common stock on Jun 12 ’24 at a price of $1.17 per share for a total of $25884.0. Following the purchase, the insider now owns 82123.0 shares.
